Gemtuzumab the conjugate represents a unique breakthrough in the approach of relapsed blood leukemia, mainly acute myeloid leukemia (AML). This novel medication combines a humanized immunoglobulin directed for the https://www.targetmol.com/compound/gemtuzumab